Payment overview · 2025
General Payments
$2,368.52
96 reported records · 18 companies
Healthcare provider profile · identity verified
Anita R Scribner, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LONGVIEW, TX · NPI 1225005705
Verified facts
What the public records show
CMS Open Payments records show Anita R Scribner, MD received $2,368.52 in general payments during 2025 across 96 reported records.
Gilead Sciences, Inc. accounted for 37.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Biktarvy, Cabenuva, Dovato, Eliquis, Ozempic, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Linzess by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Biktarvy as an associated drug or biological on 8065 records involving 2759 distinct recipient NPIs. Public Medicare Part D data also shows 289 claims for Biktarvy by this doctor in 2024.
Gilead Sciences, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Descovy as an associated drug or biological on 2032 records involving 589 distinct recipient NPIs. Public Medicare Part D data also shows 127 claims for Descovy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trelegy Ellipta by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ISENTRESS as an associated drug or biological on 37 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Isentress by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 130 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Eliquis by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CABENUVA as an associated drug or biological on 13941 records involving 3305 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Cabenuva by this doctor in 2024.
ViiV Healthcare Company reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported DOVATO as an associated drug or biological on 18732 records involving 3540 distinct recipient NPIs. Public Medicare Part D data also shows 240 claims for Dovato by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $884.61 | 37.4% | 29 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $704.28 | 29.7% | 26 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $163.72 | 6.9% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $123.78 | 5.2% | 7 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $98.49 | 4.2% | 6 | 2025 |
| Paratek Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $84.81 | 3.6% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $58.18 | 2.5% | 3 | 2025 |
| Hologic Sales and Service, LLC | Unresolved — no canonical attribution shown | $40.91 | 1.7% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $36.40 | 1.5% | 2 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $32.57 | 1.4% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $24.83 | 1.1% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $22.76 | 1.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $19.08 | 0.8% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.73 | 0.7% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $14.89 | 0.6% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.63 | 0.6% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.53 | 0.6% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $14.32 | 0.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,368.52 | 96 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Biktarvy Normalized: biktarvy |
Drug | Gilead Sciences, Inc. | $292.86 | 4 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $254.36 | 11 | 2025 |
Source payment records
|
|||||
| CABENUVA Normalized: cabenuva |
Drug | ViiV Healthcare Company | $194.94 | 12 | 2025 |
Source payment records
|
|||||
| Epclusa Normalized: epclusa |
Drug | Gilead Sciences, Inc. | $113.54 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $102.32 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $98.49 | 6 | 2025 |
Source payment records
|
|||||
| PIFELTRO Normalized: pifeltro |
Drug | Merck Sharp & Dohme LLC | $91.41 | 4 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $87.17 | 5 | 2025 |
Source payment records
|
|||||
| NUZYRA Normalized: nuzyra |
Drug | Paratek Pharmaceuticals, Inc. | $84.81 | 4 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $61.48 | 4 | 2025 |
Source payment records
|
|||||
| APTIMA Normalized: aptima |
Device | Hologic Sales and Service, LLC | $40.91 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $37.86 | 3 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $36.40 | 2 | 2025 |
Source payment records
|
|||||
| ZERBAXA Normalized: zerbaxa |
Drug | Merck Sharp & Dohme LLC | $34.45 | 2 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $32.87 | 2 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $32.87 | 2 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $32.57 | 1 | 2025 |
Source payment records
|
|||||
| RUKOBIA Normalized: rukobia |
Drug | ViiV Healthcare Company | $25.36 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $25.31 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $24.83 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $22.76 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $21.46 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.73 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.63 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.53 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $14.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Biktarvy biktarvy |
2025 | Biktarvy | 2024 | 289 | exact normalized | Medicare Part D |
| CABENUVA cabenuva |
2025 | Cabenuva | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| DOVATO dovato |
2025 | Dovato | 2024 | 240 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 130 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Biktarvy open payments reported associated product |
CMS Open Payments — General Payments 8065 supporting records · 2759 recipient NPIs · example record 1234350766 |
Biktarvy · 2024 Exact normalized brand match · 1 Part D row |
289 | 40 |
| Gilead Sciences, Inc. Exact reporting entity; no affiliate inference |
2025 | Descovy open payments reported associated product |
CMS Open Payments — General Payments 2032 supporting records · 589 recipient NPIs · example record 1234351196 |
Descovy · 2024 Exact normalized brand match · 1 Part D row |
127 | 13 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | ISENTRESS open payments reported associated product |
CMS Open Payments — General Payments 37 supporting records · 24 recipient NPIs · example record 1238003286 |
Isentress · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
130 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | CABENUVA open payments reported associated product |
CMS Open Payments — General Payments 13941 supporting records · 3305 recipient NPIs · example record 1189508908 |
Cabenuva · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| ViiV Healthcare Company Exact reporting entity; no affiliate inference |
2025 | DOVATO open payments reported associated product |
CMS Open Payments — General Payments 18732 supporting records · 3540 recipient NPIs · example record 1189508902 |
Dovato · 2024 Exact normalized brand match · 1 Part D row |
240 | 30 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Biktarvy | Bictegrav/Emtricit/Tenofov Ala | 289 | 40 |
| Dovato | Dolutegravir Sodium/Lamivudine | 240 | 30 |
| Atorvastatin Calcium | Atorvastatin Calcium | 191 | 66 |
| Tivicay | Dolutegravir Sodium | 155 | 19 |
| Amlodipine Besylate | Amlodipine Besylate | 153 | 52 |
| Symtuza | Darunavir/Cob/Emtri/Tenof Alaf | 153 | 22 |
| Doxycycline Hyclate | Doxycycline Hyclate | 152 | 66 |
| Daptomycin | Daptomycin | 132 | 27 |
| Ozempic | Semaglutide | 130 | 20 |
| Descovy | Emtricitabine/Tenofov Alafenam | 127 | 13 |
| Gabapentin | Gabapentin | 124 | 36 |
| Levofloxacin | Levofloxacin | 93 | 51 |
| Genvoya | Elviteg/Cob/Emtri/Tenof Alafen | 89 | 14 |
| Metformin Hcl | Metformin Hcl | 89 | 30 |
| Hydrochlorothiazide | Hydrochlorothiazide | 84 | 23 |
| Odefsey | Emtricitab/Rilpiviri/Tenof Ala | 82 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 24 |
| Cephalexin | Cephalexin | 73 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 28 |
| Januvia | Sitagliptin Phosphate | 72 | 17 |
| Levothyroxine Sodium | Levothyroxine Sodium | 70 | 22 |
| Metoprolol Succinate | Metoprolol Succinate | 68 | 27 |
| Darunavir | Darunavir | 66 | suppressed |
| Fluconazole | Fluconazole | 64 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 64 | 22 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 61 | 16 |
| Lisinopril | Lisinopril | 58 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 56 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 55 | 23 |
| Etravirine | Etravirine | 55 | suppressed |
| Amoxicillin | Amoxicillin | 53 | 20 |
| Ertapenem | Ertapenem Sodium | 52 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 16 |
| Ceftriaxone | Ceftriaxone Sodium | 49 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 49 | suppressed |
| Losartan Potassium | Losartan Potassium | 48 | 17 |
| Alprazolam | Alprazolam | 47 | 12 |
| Trazodone Hcl | Trazodone Hcl | 47 | 17 |
| Furosemide | Furosemide | 46 | 24 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 45 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 44 | 27 |
| Prezcobix | Darunavir/Cobicistat | 44 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 30 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 12 |
| Pregabalin | Pregabalin | 42 | 15 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 42 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 40 | suppressed |
| Ampicillin Trihydrate | Ampicillin Trihydrate | 40 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 40 | 14 |
| Celecoxib | Celecoxib | 39 | 13 |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Ritonavir | Ritonavir | 38 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 36 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 35 | suppressed |
| Cefazolin Sodium | Cefazolin Sodium | 34 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 34 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Meloxicam | Meloxicam | 33 | 15 |
| Montelukast Sodium | Montelukast Sodium | 33 | 12 |
| Tramadol Hcl | Tramadol Hcl | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | 13 |
| Omeprazole | Omeprazole | 32 | 12 |
| Isentress | Raltegravir Potassium | 31 | suppressed |
| Nystatin | Nystatin | 30 | suppressed |
| Acyclovir | Acyclovir | 29 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 29 | 15 |
| Mupirocin | Mupirocin | 29 | suppressed |
| Carvedilol | Carvedilol | 28 | suppressed |
| Levetiracetam | Levetiracetam | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | suppressed |
| Ampicillin-Sulbactam | Ampicillin Sod/Sulbactam Sod | 27 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Prezista | Darunavir | 26 | suppressed |
| Trogarzo | Ibalizumab-Uiyk | 26 | suppressed |
| Methocarbamol | Methocarbamol | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 24 | 13 |
| Potassium Chloride | Potassium Chloride | 24 | 13 |
| Vancomycin Hcl | Vancomycin Hcl | 24 | suppressed |
| Atenolol | Atenolol | 23 | suppressed |
| Clonazepam | Clonazepam | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 23 | suppressed |
| Eliquis | Apixaban | 22 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 22 | suppressed |
| Simvastatin | Simvastatin | 22 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 21 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Oxacillin Sodium | Oxacillin Sodium | 21 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 21 | suppressed |
| Prednisone | Prednisone | 21 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 21 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Cabenuva | Cabotegravir/Rilpivirine | 20 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 20 | suppressed |
| Xarelto | Rivaroxaban | 20 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 19 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 16 | suppressed |
| Fenofibrate | Fenofibrate | 16 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 16 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 15 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 15 | suppressed |
| Dapsone | Dapsone | 14 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 14 | suppressed |
| Dicloxacillin Sodium | Dicloxacillin Sodium | 14 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 14 | suppressed |
| Arikayce | Amikacin Liposomal/Neb.Accessr | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Evotaz | Atazanavir Sulfate/Cobicistat | 13 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 13 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 13 | suppressed |
| Linzess | Linaclotide | 13 | suppressed |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Ondansetron Odt | Ondansetron | 12 | suppressed |
| Testosterone | Testosterone | 12 | suppressed |
| Abacavir-Lamivudine | Abacavir Sulfate/Lamivudine | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 11 | suppressed |
| Linezolid | Linezolid | 11 | suppressed |
| Pfizerpen | Penicillin G Potassium | 11 | suppressed |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 11 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 11 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,368.52 · 96 records | Gilead Sciences, Inc. | AIRSUPRA, APTIMA, AUSTEDO XR, Biktarvy, CABENUVA, CAPVAXIVE, DOVATO, ELIQUIS, Epclusa, GARDASIL 9, Heplisav-B, JARDIANCE, Kerendia, MAVYRET, NURTEC ODT, NUZYRA, OTEZLA, Ozempic, PIFELTRO, QULIPTA, REPATHA, REZDIFFRA, RUKOBIA, Rybelsus, TRELEGY ELLIPTA, TZIELD, UBRELVY, VOQUEZNA, Wegovy, ZERBAXA | 11 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Biktarvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error